Director / Editor: Victor Teboul, Ph.D.
Looking inside ourselves and out at the world
Independent and neutral with regard to all political and religious orientations,® aims to promote awareness of the major democratic principles on which tolerance is based.

AstraZeneca, Germany and over-65s: how to interpret confusing vaccine data

By Simon Kolstoe, Senior Lecturer in Evidence-Based Healthcare and University Ethics Advisor, University of Portsmouth
Share this article
Germany has recently announced that it will not offer the AstraZeneca COVID-19 jab to over-65s due to insufficient data about its efficacy in that age group.

Meanwhile, initial data from Israel seemed to suggest that 14 days after the Pfizer/BioNTech first vaccine dose, patients only had a 33% reduced chance of infection – disappointingly…

Read complete article

© The Conversation -

Follow us on ...
Facebook Twitter